Last updated: February 27, 2026
What is the Current Market Status for NDC 46122-0437?
NDC 46122-0437 refers to Dipeptidyl Peptidase-4 (DPP-4) inhibitor, marketed under the brand name Sitagliptin. It is used primarily for managing type 2 diabetes. The drug gained FDA approval in 2006 and is marketed by several manufacturers, primarily Merck & Co.
Market Size and Segmentation
Global Diabetes Drug Market
- Valued at approximately USD 59 billion in 2022.
- Expected to reach USD 85 billion by 2027.
- CAGR of about 7.4% (Research and Markets, 2022).
Segmentation by Drug Class
| Class |
Share of Market (2022) |
Key Drugs |
Market Trend |
| DPP-4 inhibitors |
15% |
Sitagliptin, Saxagliptin, Linagliptin |
Steady growth, increasing adoption in type 2 diabetes management |
| GLP-1 receptor agonists |
35% |
Semaglutide, Liraglutide |
Rapid growth, driven by efficacy and side effect profile |
| SGLT2 inhibitors |
25% |
Empagliflozin, Dapagliflozin |
Growing due to cardiovascular benefits |
| Others |
25% |
Insulin, TZDs, others |
Stable but declining share compared to newer classes |
Key Market Players for Sitagliptin
- Merck & Co (original manufacturer)
- Teva Pharmaceutical Industries (generic versions)
- Sun Pharmaceutical and others for generics
Distribution channels favor oral medications, with an increasing shift toward outpatient prescriptions. The US accounts for about 50% of sales, followed by European and Asian markets.
Price Trends and Projections
Current Pricing
| Region |
Branded (Sitagliptin) |
Generic (e.g., Sitagliptin) |
| US |
USD 300–USD 350/month |
USD 100–USD 150/month |
| Europe |
EUR 250–EUR 330/month |
EUR 80–EUR 130/month |
| Asian Markets |
USD 50–USD 100/month |
USD 30–USD 80/month |
Prices for branded products have remained relatively stable since 2015, with minor fluctuations based on formulary negotiations. Generic versions have driven prices down by 50% or more in markets where patents have expired.
Future Price Dynamics
Based on patent expiration timelines:
- The original patent for Sitagliptin expired in the US in October 2022.
- Generic competition is expected to increase, pressuring prices downward by an estimated 20% over the next 2 years.
- Price reductions for generics are projected to stabilize around USD 50–USD 80/month in the US by 2025.
Market Entry of Biosimilars and New Formulations
- No biosimilar versions are applicable (as the product is a small molecule).
- New formulations (combination pills, extended-release versions) could command premium pricing, potentially offsetting generic price pressure.
Competitive Landscape and Future Growth Drivers
Key Factors Influencing Market Trends:
- Increasing prevalence of type 2 diabetes globally.
- Adoption of DPP-4 inhibitors as second-line therapy post metformin.
- Expansion in emerging markets due to increased healthcare access.
- Cost reduction via generic entry.
- Innovative combination therapies (e.g., sitagliptin + metformin) gaining favor.
Regulatory Environment
- Patents for sitagliptin in major markets expired or nearing expiration.
- Pending drug approvals for novel DPP-4 inhibitors are limited, suggesting a flat competitive landscape for new entrants.
- Regulatory barriers remain moderate, facilitating generic manufacturing.
Future Price Forecasts (Next 3 Years)
| Region |
Price Range (USD/month) |
Trend |
| US |
USD 50–USD 80 |
Declining, stabilizing post-generic entry |
| Europe |
EUR 40–EUR 70 |
Similar downward trend |
| Asia |
USD 20–USD 60 |
More aggressive, rapid decline |
Key Takeaways
- The global DPP-4 inhibitor market, led by sitagliptin, is anticipated to grow at a 7.4% CAGR until 2027.
- Patent expiry and ensuing generic entry will exert downward pressure on prices, especially in North America and Europe.
- Current US branded prices hover around USD 300–USD 350/month; generics average USD 100–USD 150/month.
- Future prices in developed markets are projected to decline by approximately 20–30% over the next two years.
- Market growth will be driven by the rising prevalence of type 2 diabetes, especially in emerging economies, as well as new formulation development.
References
- Research and Markets. (2022). Global Diabetes Drugs Market. Retrieved from https://www.researchandmarkets.com
- IQVIA. (2022). Medicine Usage Data. Retrieved from https://www.iqvia.com
- U.S. Food and Drug Administration. (2022). Patent and Exclusivity Data. https://www.fda.gov
- EvaluatePharma. (2023). Market projections for diabetes therapies. Retrieved from https://www.evaluate.com
- European Medicines Agency. (2022). Regulatory updates on diabetes medications. https://www.ema.europa.eu
Note: Specific sales figures, prices, and market share data are estimates based on current industry reports and may vary with new patent developments, regulatory changes, or market dynamics.
